ストックスクリーナーアプリを入手
77.95
1.23%
0.93
アフターアワーズ：
77.93
-0.02
-0.03%
前日終値:
$77.02
開ける：
$77.51
24時間の取引高:
6.61M
Relative Volume:
0.80
時価総額：
$99.12B
収益：
$402.11B
当期純損益:
$1.73B
株価収益率:
56.53
EPS:
1.3789
ネットキャッシュフロー:
$7.81B
1週間 パフォーマンス:
+2.14%
1か月 パフォーマンス:
-2.98%
6か月 パフォーマンス:
+19.01%
1年 パフォーマンス:
+23.32%
1日の値動き範囲:
$77.08
$79.06
1週間の範囲:
$73.00
$79.06
52週間の値動き範囲:
$58.35
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Compare CVS vs UNH, CI, ELV, HUM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
77.91 | 97.99B | 402.11B | 1.73B | 7.81B | 1.3789 |
|
UNH
Unitedhealth Group Inc
|
284.49 | 252.65B | 447.57B | 12.81B | 16.08B | 13.19 |
|
CI
Cigna Group
|
287.49 | 77.65B | 216.66B | 6.25B | 7.44B | 22.19 |
|
ELV
Elevance Health Inc
|
336.04 | 72.89B | 199.13B | 5.66B | 3.17B | 25.11 |
|
HUM
Humana Inc
|
179.00 | 21.10B | 126.36B | 1.30B | 1.55B | 10.67 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-14 | 開始されました | Goldman | Buy |
| 2025-08-18 | アップグレード | UBS | Neutral → Buy |
| 2025-08-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | アップグレード | Edward Jones | Hold → Buy |
| 2024-12-03 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-11-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-10-04 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-30 | 開始されました | Robert W. Baird | Neutral |
| 2024-05-07 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-05-02 | ダウングレード | UBS | Buy → Neutral |
| 2024-05-01 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | 開始されました | Barclays | Equal Weight |
| 2024-02-26 | 開始されました | Leerink Partners | Outperform |
| 2023-12-22 | 開始されました | HSBC Securities | Buy |
| 2023-09-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-09-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | ダウングレード | Edward Jones | Buy → Hold |
| 2023-05-26 | 開始されました | Piper Sandler | Overweight |
| 2023-04-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-11-23 | 再開されました | Morgan Stanley | Overweight |
| 2022-06-17 | 開始されました | Loop Capital | Buy |
| 2022-05-27 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-02-11 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | 開始されました | Goldman | Buy |
| 2021-12-01 | 開始されました | Seaport Research Partners | Buy |
| 2021-05-19 | 開始されました | Wells Fargo | Equal Weight |
| 2021-03-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-01-08 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-17 | 開始されました | Piper Sandler | Overweight |
| 2020-07-01 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-05-14 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-09-12 | 開始されました | Deutsche Bank | Buy |
| 2019-06-05 | アップグレード | Standpoint Research | Hold → Buy |
| 2019-04-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | 開始されました | Guggenheim | Buy |
| 2019-04-15 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2019-04-10 | 繰り返されました | BofA/Merrill | Buy |
| 2019-03-13 | 開始されました | Bernstein | Outperform |
| 2019-02-20 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | 開始されました | UBS | Buy |
| 2018-12-18 | 開始されました | Barclays | Overweight |
| 2018-11-29 | 再開されました | Goldman | Neutral |
| 2018-11-28 | 開始されました | Evercore ISI | Outperform |
| 2018-10-26 | 再開されました | Wolfe Research | Peer Perform |
| 2018-07-09 | アップグレード | Citigroup | Neutral → Buy |
| 2018-02-27 | 再開されました | BofA/Merrill | Buy |
| 2018-02-13 | 繰り返されました | Citigroup | Neutral |
すべてを表示
Cvs Health Corp (CVS) 最新ニュース
Big Health Raises $23.7M from .406 Ventures, AlleyCorp, CVS Ventures, Blue Venture Fund - Behavioral Health Business
Analysts See Multiple Growth Levers For CVS In 2026 - Benzinga
Analysts See Multiple Growth Levers For CVS Health In 2026 - Benzinga
Is CVS’s Reaffirmed 2026 EPS Guidance Amid Medicare Advantage Uncertainty Altering The Investment Case For CVS Health (CVS)? - Yahoo Finance
Humana’s profit outlook adds to health insurance gloom - Modern Healthcare News
CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook - Finviz
Mark Cuban Urges Trump To 'Put His Weight Behind' Josh Hawley, Elizabeth Warren's 'Break Up Big Medicine Act' - Benzinga
Decoding CVS Health Corp (CVS): A Strategic SWOT Insight - GuruFocus
CVS defends its scale as CEO Joyner aligns with Trump, blames pharma for high costs - The Business Journals
CVS Health Earnings Call: Cash, Growth And Cost Risks - TipRanks
CVS annual profit guidance misses Wall Street estimates - The Boston Globe
CVS Health Corp (CVS) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
CVS Reiterates 2026 Profit Outlook, Shares Slide 3.7% Despite Q4 Beat - TradingView
CVS year-end profit falls to $1.7B in 2025 - Providence Business News
What's Going On With CVS Health Stock Tuesday?CVS Health (NYSE:CVS) - Benzinga
House subpoenas CVS, Kaiser Permanente, others in ACA fraud probe - Modern Healthcare News
Gold Moves Lower; CVS Health Earnings Top Views - Benzinga
CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline - AlphaStreet News
CVS Health (CVS) Surpasses Expectations with Strong 2025 Performance - GuruFocus
CVS Health grapples with high costs, strategic reset - Modern Healthcare News
CVS Health Reports Strong Q4 2025 Earnings with Positive Outlook - Intellectia AI
CVS Earnings: 2026 Guidance Maintained After Strong Trends In Late 2025 - Morningstar
CVS Anticipates Medicare Margin Growth by 2026 - GuruFocus
CVS Faces Challenges with Proposed Rates Amid Rising Costs - GuruFocus
Jim Cramer on CVS: "I Think It's a Fascinating Time to Own the Stock" - Finviz
Jim Cramer on CVS: “I Think It’s a Fascinating Time to Own the Stock” - Insider Monkey
CVS Health Q4 2025 slides: Revenue jumps 8.2%, stock falls despite earnings beat - Investing.com
CVS Health posts strong Q4 revenue, raises full-year guidance - Proactive financial news
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
CVS Keeps 2026 Forecast Steady Amid Tumult in Health Insurance - Bloomberg.com
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips - Investing.com
CVS Health (CVS) Subpoenaed in ACA Fraud Investigation - GuruFocus
AI for investors - MLQ.ai
CVS Beats Q4 Revenue Estimates, Highlights Strategic Growth - GuruFocus
CVS Forecasts FY26 Operating Income in Billions - GuruFocus
CVS Maintains FY26 Effective Tax Rate Projection at 25.3% - GuruFocus
Republican-led House panel issues subpoenas to eight health insurers: Axios - CNBC
CVS Health Reports Q4 Beat but Maintains Full-Year Outlook - Intellectia AI
CVS Health (NYSE:CVS) Surprises With Q4 CY2025 Sales - Finviz
CVS Health Corp (NYSE:CVS) Beats Q4 Estimates but Shares Dip on Cautious Outlook - ChartMill
CVS Lowers Fiscal Year 2026 Cash Flow Outlook - GuruFocus
CVS Health (CVS) Surpasses Q4 Expectations with Strong Revenue G - GuruFocus
CVS Health beats Q4 expectations, cash flow guidance lowered - Investing.com
CVS Health Insiders Placed Bullish Bets Worth US$2.10m - Yahoo Finance
CVS Health beats quarterly profit expectations on pharmacy performance By Reuters - Investing.com
CVS HEALTH Corp SEC 10-K Report - TradingView
CVS Health Corp earnings beat by $0.09, revenue topped estimates - Investing.com
CVS Health keeps in place 2026 forecast, eyes topping it - Reuters
CVS Health beats quarterly profit expectations on pharmacy performance - Yahoo Finance
CVS posts Q4 sales of $105.7B, up 8.2% - breakingthenews.net
US House panel issues subpoenas to eight health insurers on alleged Obamacare fraud - Reuters
Cvs Health Corp (CVS) 財務データ
収益
当期純利益
現金流量
EPS
2.45%
1.81%
大文字化:
|
ボリューム (24 時間):